US2021196859A1PendingUtilityA1
Cardiovascular Prostheses
Assignee: CORMATRIX CARDIOVASCULAR INCPriority: Dec 16, 2011Filed: Feb 18, 2021Published: Jul 1, 2021
Est. expiryDec 16, 2031(~5.4 yrs left)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61K 31/4418A61L 27/34A61F 2/06A61F 2250/0067A61L 27/3633A61F 2210/0004A61L 27/58A61L 27/54A61L 2430/20A61L 2300/414A61L 27/507A61L 27/3834A61F 2/0095A61F 2/00
78
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue that include a plurality of particulate structures. The particulate structures further include an acellular ECM core and an outer layer or coating comprising poly(glycerol sebacate) (PGS) and everolimus. When the particulate structures are delivered to the damaged cardiovascular tissue the outer layer is adapted to induce a first level of remodeling and suppress hyperplasia, and the acellular ECM is adapted to induce a second level of remodeling.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A cardiovascular prosthesis, consisting of:
a plurality of biodegradable particulate structures, each of said plurality of particulate structures consisting of a first tissue remodeling inducing composition and a second tissue remodeling inducing composition, said second tissue remodeling inducing composition being encased in said first tissue remodeling inducing composition, wherein each of said plurality of particulate structures comprises a core consisting of said second tissue remodeling inducing composition and an outer layer consisting of said first tissue remodeling inducing composition, said first tissue remodeling inducing composition consisting of an ECM-mimicking composition, said ECM-mimicking composition consisting of poly(glycerol sebacate) (PGS) and everolimus, said everolimus consisting of greater than 0.001 wt. % of said ECM-mimicking composition, said second tissue remodeling inducing composition consisting of acellular ECM derived from a mammalian tissue source, said first remodeling inducing composition, when delivered to damaged cardiovascular tissue, adapted to induce a first level of remodeling of said damaged cardiovascular tissue and suppress hyperplasia, said second tissue remodeling inducing composition, when delivered to said damaged cardiovascular tissue, adapted to modulate inflammation of said damaged cardiovascular tissue and induce a second level of remodeling of said damaged cardiovascular tissue.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.